Xalkori (crizotinib) — Medica
Non-Small Cell Lung Cancer – ROS1 Rearrangement-Positive
Initial criteria
- age ≥ 18 years
- advanced or metastatic disease
- disease is ROS1 rearrangement-positive
- mutation detected by an approved test
Approval duration
1 year